Stocks
Axsome Therapeutics (AXSM) EV/EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -11.1 | 0.61 | 0.89 | -14.4 | -53.6 | -49.6 | ||
| Changes by years, y/y, % | -62% | -105% | +47% | -1 724% | +271% | +13.1% | |||
Axsome Therapeutics. EV/EBITDA
Axsome Therapeutics. EV/EBITDA, changes, %
Axsome Therapeutics (AXSM) EV/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | LTM ? | |||
| EV/EBITDA | ? | -22.2 | -28.1 | -55.1 | -49.6 | -69.6 | -49.6 | |
| Changes by years, y/y, % | -5 451% | +100% | +277% | +132% | +213% | |||
| Changes by quarters, q/q, % | +4% | +27% | +96% | -10% | +40% | |||
